Literature DB >> 22972985

IFNγR signaling mediates alloreactive T-cell trafficking and GVHD.

Jaebok Choi1, Edward D Ziga, Julie Ritchey, Lynne Collins, Julie L Prior, Matthew L Cooper, David Piwnica-Worms, John F DiPersio.   

Abstract

The clinical goal of allogeneic hematopoietic stem cell transplantation (allo-HSCT) is to minimize GVHD while maintaining GvL. Here, we show that interferon γ receptor-deficient (IFNγR(-/-)) allogeneic Tconv, which possess normal alloreactivity and cytotoxicity, induce significantly less GVHD than wild-type (WT) Tconv. This effect is mediated by altered trafficking of IFNγR(-/-) Tconv to GVHD target organs, especially the gastrointestinal (GI) tract. We show that the chemokine receptor CXCR3 is induced via IFNγR-mediated signaling and partially contributes to the trafficking of WT Tconv to GVHD target organs. Indeed, CXCR3(-/-) Tconv recapitulate the reduced GVHD potential of IFNγR(-/-) Tconv in a minor-mismatched GVHD model. Most importantly, IFNγR(-/-) (and CXCR3(-/-)) Tconv mediate a robust and beneficial GvL effect. In addition, we show that IFNγR(-/-) regulatory T cells (Tregs) are fully suppressive in vitro although defective in suppressor function in vivo and that WT Tregs suppress GVHD in vivo only when allogeneic Tconv produce interferon γ (IFNγ), suggesting that the IFNγR signaling pathway is the major mechanism for both Tregs and Tconv to migrate to GVHD target organs. Finally, pharmacologic inhibition of IFNγR signaling with inhibitors of JAK1/JAK2, which are mediators of IFNγR signaling, results in the decreased expression of CXCR3 and reduced GVHD and improved survival after allo-HSCT and this effect is mediated by altered trafficking of Tconv to GVHD target organs.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22972985      PMCID: PMC3496960          DOI: 10.1182/blood-2012-01-403196

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  50 in total

1.  Interferon-gamma and interferon-gamma receptor 1 and 2 gene polymorphisms and restenosis following coronary stenting.

Authors:  K Tiroch; N von Beckerath; W Koch; J Lengdobler; A Joost; A Schömig; A Kastrati
Journal:  Atherosclerosis       Date:  2005-02-24       Impact factor: 5.162

2.  CXCR3 polymorphisms associated with risk of asthma.

Authors:  Hyun Sub Cheong; Choon-Sik Park; Lyoung Hyo Kim; Byung Lae Park; Soo-Taek Uh; Yong Hooun Kim; Gune-Il Lym; Jong-Young Lee; Jong-Keuk Lee; Hung Tae Kim; Ha-Jung Ryu; Bok Ghee Han; Jun Woo Kim; Chan Park; Kuchan Kimm; Hyoung Doo Shin; Bermseok Oh
Journal:  Biochem Biophys Res Commun       Date:  2005-09-09       Impact factor: 3.575

3.  Real-time imaging of ligand-induced IKK activation in intact cells and in living mice.

Authors:  Shimon Gross; David Piwnica-Worms
Journal:  Nat Methods       Date:  2005-08       Impact factor: 28.547

Review 4.  Role of Interferon-gamma in GVHD and GVL.

Authors:  Yong-Guang Yang; Hui Wang; Wannee Asavaroengchai; Bimalangshu R Dey
Journal:  Cell Mol Immunol       Date:  2005-10       Impact factor: 11.530

Review 5.  Leukocyte migration and graft-versus-host disease.

Authors:  Christian A Wysocki; Angela Panoskaltsis-Mortari; Bruce R Blazar; Jonathan S Serody
Journal:  Blood       Date:  2005-02-08       Impact factor: 22.113

6.  Cutting edge: contact-mediated suppression by CD4+CD25+ regulatory cells involves a granzyme B-dependent, perforin-independent mechanism.

Authors:  David C Gondek; Li-Fan Lu; Sergio A Quezada; Shimon Sakaguchi; Randolph J Noelle
Journal:  J Immunol       Date:  2005-02-15       Impact factor: 5.422

7.  Immune response in mice that lack the interferon-gamma receptor.

Authors:  S Huang; W Hendriks; A Althage; S Hemmi; H Bluethmann; R Kamijo; J Vilcek; R M Zinkernagel; M Aguet
Journal:  Science       Date:  1993-03-19       Impact factor: 47.728

8.  Interferon-gamma receptor-1 gene promoter polymorphisms (G-611A; T-56C) and susceptibility to tuberculosis.

Authors:  L Bulat-Kardum; G E Etokebe; J Knezevic; S Balen; N Matakovic-Mileusnic; L Zaputovic; J Pavelic; Z Beg-Zec; Z Dembic
Journal:  Scand J Immunol       Date:  2006-02       Impact factor: 3.487

9.  Galectin-1: a key effector of regulation mediated by CD4+CD25+ T cells.

Authors:  Marina I Garín; Chung-Ching Chu; Dela Golshayan; Eva Cernuda-Morollón; Robin Wait; Robert I Lechler
Journal:  Blood       Date:  2006-11-16       Impact factor: 22.113

10.  Mice from a genetically resistant background lacking the interferon gamma receptor are susceptible to infection with Leishmania major but mount a polarized T helper cell 1-type CD4+ T cell response.

Authors:  K Swihart; U Fruth; N Messmer; K Hug; R Behin; S Huang; G Del Giudice; M Aguet; J A Louis
Journal:  J Exp Med       Date:  1995-03-01       Impact factor: 14.307

View more
  60 in total

1.  Over-salting ruins the balance of the immune menu.

Authors:  Booki Min; Robert L Fairchild
Journal:  J Clin Invest       Date:  2015-10-20       Impact factor: 14.808

2.  A phase 1 trial of itacitinib, a selective JAK1 inhibitor, in patients with acute graft-versus-host disease.

Authors:  Mark A Schroeder; H Jean Khoury; Madan Jagasia; Haris Ali; Gary J Schiller; Karl Staser; Jaebok Choi; Leah Gehrs; Michael C Arbushites; Ying Yan; Peter Langmuir; Nithya Srinivas; Michael Pratta; Miguel-Angel Perales; Yi-Bin Chen; Gabrielle Meyers; John F DiPersio
Journal:  Blood Adv       Date:  2020-04-28

Review 3.  New and emerging therapies for acute and chronic graft versus host disease.

Authors:  LaQuisa Hill; Amin Alousi; Partow Kebriaei; Rohtesh Mehta; Katayoun Rezvani; Elizabeth Shpall
Journal:  Ther Adv Hematol       Date:  2017-11-28

4.  JAK-STAT-mediated chronic inflammation impairs cytotoxic T lymphocyte activation to decrease anti-PD-1 immunotherapy efficacy in pancreatic cancer.

Authors:  Chunwan Lu; Asif Talukder; Natasha M Savage; Nagendra Singh; Kebin Liu
Journal:  Oncoimmunology       Date:  2017-02-10       Impact factor: 8.110

5.  JAK2 expression is associated with tumor-infiltrating lymphocytes and improved breast cancer outcomes: implications for evaluating JAK2 inhibitors.

Authors:  Chris P Miller; Jason D Thorpe; Amanda N Kortum; Catherine M Coy; Wei-Yi Cheng; Tai-Hsien Ou Yang; Dimitris Anastassiou; J David Beatty; Nicole D Urban; C Anthony Blau
Journal:  Cancer Immunol Res       Date:  2014-01-15       Impact factor: 11.151

6.  Azacitidine Mitigates Graft-versus-Host Disease via Differential Effects on the Proliferation of T Effectors and Natural Regulatory T Cells In Vivo.

Authors:  Matthew L Cooper; Jaebok Choi; Darja Karpova; Kiran Vij; Julie Ritchey; Mark A Schroeder; John F DiPersio
Journal:  J Immunol       Date:  2017-03-22       Impact factor: 5.422

7.  Essential role of IFN-γ in T cell-associated intestinal inflammation.

Authors:  Yoshihiro Eriguchi; Kiminori Nakamura; Yuki Yokoi; Rina Sugimoto; Shuichiro Takahashi; Daigo Hashimoto; Takanori Teshima; Tokiyoshi Ayabe; Michael E Selsted; André J Ouellette
Journal:  JCI Insight       Date:  2018-09-20

8.  The P2X7 receptor antagonist Brilliant Blue G reduces serum human interferon-γ in a humanized mouse model of graft-versus-host disease.

Authors:  N J Geraghty; L Belfiore; D Ly; S R Adhikary; S J Fuller; W Varikatt; M L Sanderson-Smith; V Sluyter; S I Alexander; R Sluyter; D Watson
Journal:  Clin Exp Immunol       Date:  2017-07-24       Impact factor: 4.330

9.  Upregulation of IFN-Inducible and Damage-Response Pathways in Chronic Graft-versus-Host Disease.

Authors:  Frances T Hakim; Sarfraz Memon; Ping Jin; Matin M Imanguli; Huan Wang; Najibah Rehman; Xiao-Yi Yan; Jeremy Rose; Jacqueline W Mays; Susan Dhamala; Veena Kapoor; William Telford; John Dickinson; Sean Davis; David Halverson; Haley B Naik; Kristin Baird; Daniel Fowler; David Stroncek; Edward W Cowen; Steven Z Pavletic; Ronald E Gress
Journal:  J Immunol       Date:  2016-09-30       Impact factor: 5.422

10.  Comparative analysis of FoxP3(+) regulatory T cells in the target tissues and blood in chronic graft versus host disease.

Authors:  M M Imanguli; E W Cowen; J Rose; S Dhamala; W Swaim; S Lafond; B Yagi; R E Gress; S Z Pavletic; F T Hakim
Journal:  Leukemia       Date:  2014-02-28       Impact factor: 11.528

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.